Beauty Health (NASDAQ:SKIN) Shares Down 1.4% – Here’s Why

The Beauty Health Company (NASDAQ:SKIN)’s share price traded down 1.4% on Monday . The company traded as low as $1.42 and last traded at $1.44. 422,635 shares changed hands during trading, a decline of 37% from the average session volume of 671,696 shares. The stock had previously closed at $1.46.

Beauty Health News Summary

Here are the key news stories impacting Beauty Health this week:

• Positive Sentiment: Growing preventive skincare adoption in India signals expanding addressable market and earlier lifetime customer engagement, which could support longer-term service and product revenue for companies in the professional-beauty channel. Read More.
• Positive Sentiment: Industry forecasts listing the top beauty trends for 2026 point to sustained consumer interest and innovation (routine upgrades, tech-enabled treatments), a tailwind for companies selling new treatments and clinical devices. Read More.
• Positive Sentiment: Seasonal and barrier-skin concerns (winter damage, modern environmental causes) tend to raise short-term demand for corrective treatments and dermatologist-recommended products, supporting quarterly revenue cadence in cold months. Read More.
• Neutral Sentiment: Broad consumer education pieces on modern-skin causes and beauty resolutions increase awareness but are non-specific on channel — could benefit both pro services and mass-market brands. Read More.
• Neutral Sentiment: Articles highlighting niche ingredients or benefits (espresso skin benefits, mindful skincare resolutions) boost category interest but are unlikely to move a single stock materially on their own. Read More.
• Neutral Sentiment: Influencer-driven pieces (Kardashian/Jenner tips) can amplify demand episodically; useful for marketing but unpredictable for professional channels. Read More.
• Neutral Sentiment: Coverage of DIY risks and cosmetic overuse highlights a double-edged trend: consumer experimentation can cut into professional spend, but reported harm often drives people back to clinicians for corrective treatments. Read More.
• Negative Sentiment: Product-review and “best at-home mask” articles spotlight affordable consumer products (eye masks, collagen masks) that compete with professional services and could pressure spend per customer if at-home substitutes gain share. Read More. Read More.

Wall Street Analysts Forecast Growth

SKIN has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of Beauty Health from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Roth Capital started coverage on Beauty Health in a research report on Friday, September 19th. They set a “buy” rating and a $3.50 target price for the company. Zacks Research lowered Beauty Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 19th. TD Cowen lifted their price target on Beauty Health from $2.00 to $2.50 and gave the company a “hold” rating in a research report on Monday, September 22nd. Finally, Cowen restated a “hold” rating on shares of Beauty Health in a research report on Monday, September 22nd. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $2.81.

Beauty Health Trading Down 1.4%

The stock has a 50 day moving average of $1.41 and a 200 day moving average of $1.74. The company has a debt-to-equity ratio of 5.53, a current ratio of 4.98 and a quick ratio of 4.07. The firm has a market cap of $183.60 million, a P/E ratio of -6.55 and a beta of 1.18.

Beauty Health (NASDAQ:SKIN) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The firm had revenue of $70.66 million during the quarter, compared to analysts’ expectations of $68.33 million. Beauty Health had a negative return on equity of 19.70% and a negative net margin of 3.87%. As a group, equities research analysts predict that The Beauty Health Company will post -0.25 EPS for the current year.

Institutional Investors Weigh In On Beauty Health

A number of hedge funds have recently made changes to their positions in the business. Public Employees Retirement System of Ohio purchased a new stake in shares of Beauty Health in the 3rd quarter valued at $26,000. Franklin Resources Inc. bought a new stake in Beauty Health in the third quarter worth $31,000. Zacks Investment Management purchased a new stake in Beauty Health during the third quarter valued at about $35,000. Ameriprise Financial Inc. purchased a new stake in Beauty Health during the third quarter valued at about $38,000. Finally, AQR Capital Management LLC bought a new position in shares of Beauty Health during the first quarter valued at about $40,000. 93.26% of the stock is currently owned by institutional investors.

Beauty Health Company Profile

Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.

Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.